When tumor tissue from NSCLC patients harbors activating EGFR gene mutations, these can be treated with tyrosine kinase inhibitors (TKIs), such as gefitinib and afatinib (Beagan et al., 2020). The gene discussed is EGFR; the disease is neoplasm.